ID: ALA5188502

Max Phase: Preclinical

Molecular Formula: C26H22Cl2N4O2S

Molecular Weight: 525.46

Representations

Canonical SMILES:  O=C(NCc1cccs1)[C@@H]1CN(C(=O)c2cncc3ccccc23)CCN1c1ccc(Cl)c(Cl)c1

Standard InChI:  InChI=1S/C26H22Cl2N4O2S/c27-22-8-7-18(12-23(22)28)32-10-9-31(16-24(32)25(33)30-14-19-5-3-11-35-19)26(34)21-15-29-13-17-4-1-2-6-20(17)21/h1-8,11-13,15,24H,9-10,14,16H2,(H,30,33)/t24-/m0/s1

Standard InChI Key:  RINFEVYWSYRNHT-DEOSSOPVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 525.46

Molecular Weight (Monoisotopic): 524.0841

AlogP: 5.25

#Rotatable Bonds: 5

Polar Surface Area: 65.54

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 13.11

CX Basic pKa: 3.94

CX LogP: 4.73

CX LogD: 4.73

Aromatic Rings: 4

Heavy Atoms: 35

QED Weighted: 0.39

Np Likeness Score: -1.92

References

1. Gao S, Sylvester K, Song L, Claff T, Jing L, Woodson M, Weiße RH, Cheng Y, Schäkel L, Petry M, Gütschow M, Schiedel AC, Sträter N, Kang D, Xu S, Toth K, Tavis J, Tollefson AE, Müller CE, Liu X, Zhan P..  (2022)  Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.,  65  (19.0): [PMID:36107752] [10.1021/acs.jmedchem.2c01146]

Source

Source(1):

• Scientific Literature